Luspatercept (mIgG2a)
Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects[1].
Product Specifications
CAS Number
[1373715-00-4]
Product Name Alternative
RAP-536
UNSPSC
12352203
Target
TGF-beta/Smad
Related Pathways
Stem Cell/Wnt; TGF-beta/Smad
Field of Research
Metabolic Disease
Smiles
[Luspatercept(mIgG2a)]
References & Citations
[1]Suragani RN, et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia. Blood. 2014 Jun 19; 123 (25) :3864-72.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
